Petros Kampanis

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

Sæmundur Rögnvaldsson, Þorvarður Jón Löve, Sigrún Þorsteinsdóttir et al. · Blood Cancer Journal · 2021 · 109 citations · Full text

FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53

Anna Maria Ochocka, Petros Kampanis, Samantha M. Nicol et al. · FEBS Letters · 2009 · 66 citations

A novel site of AKT‐mediated phosphorylation in the human MDM2 onco‐protein

Diane Milne, Petros Kampanis, Samantha M. Nicol et al. · FEBS Letters · 2004 · 47 citations · Full text

Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Sigurður Y. Kristinsson, Sæmundur Rögnvaldsson, Sigrún Þorsteinsdóttir et al. · Blood · 2021 · 19 citations

Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Sigrún Þorsteinsdóttir, Gauti Kjartan Gíslason, Thor Aspelund et al. · Blood · 2021 · 13 citations